CTI BioPharma Corp. (NASDAQ:CTIC) went up by 5.69% from its latest closing price compared to the recent 1-year high of $6.52. The company’s stock price has collected 3.03% of gains in the last five trading sessions.
Is It Worth Investing in CTI BioPharma Corp. (NASDAQ :CTIC) Right Now?
Plus, the 36-month beta value for CTIC is at 0.86. Opinions of the stock are interesting as 6 analysts out of 6 who provided ratings for CTI BioPharma Corp. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $9.58, which is $3.45 above the current price. CTIC currently public float of 74.15M and currently shorts hold a 17.56% ratio of that float. Today, the average trading volume of CTIC was 3.89M shares.
CTIC’s Market Performance
CTIC stocks went up by 3.03% for the week, with a monthly jump of 38.37% and a quarterly performance of 46.65%, while its annual performance rate touched 165.37%. The volatility ratio for the week stands at 9.92% while the volatility levels for the past 30 days are set at 9.51% for CTI BioPharma Corp. The simple moving average for the period of the last 20 days is 11.37% for CTIC stocks with a simple moving average of 82.78% for the last 200 days.
Analysts’ Opinion of CTIC
Many brokerage firms have already submitted their reports for CTIC stocks, with BTIG Research repeating the rating for CTIC by listing it as a “Buy.” The predicted price for CTIC in the upcoming period, according to BTIG Research is $7 based on the research report published on August 09th of the previous year 2021.
Stifel, on the other hand, stated in their research note that they expect to see CTIC reach a price target of $5.50. The rating they have provided for CTIC stocks is “Buy” according to the report published on May 06th, 2021.
JMP Securities gave a rating of “Mkt Outperform” to CTIC, setting the target price at $3 in the report published on June 24th of the previous year.
CTIC Trading at 21.99% from the 50-Day Moving Average
After a stumble in the market that brought CTIC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -5.98% of loss for the given period.
Volatility was left at 9.51%, however, over the last 30 days, the volatility rate increased by 9.92%, as shares surge +25.87% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +27.71% upper at present.
During the last 5 trading sessions, CTIC rose by +3.03%, which changed the moving average for the period of 200-days by +94.60% in comparison to the 20-day moving average, which settled at $5.57. In addition, CTI BioPharma Corp. saw 147.18% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at CTIC starting from KIRSKE DAVID, who sale 60,000 shares at the price of $6.21 back on Jun 17. After this action, KIRSKE DAVID now owns 7,397 shares of CTI BioPharma Corp., valued at $372,505 using the latest closing price.
KIRSKE DAVID, the EVP, Chief Financial Officer of CTI BioPharma Corp., sale 10,000 shares at $5.50 during a trade that took place back on Jun 14, which means that KIRSKE DAVID is holding 7,397 shares at $55,000 based on the most recent closing price.
Stock Fundamentals for CTIC
Equity return is now at value -616.50, with -123.20 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 1.03.